A Glycoprotein subunit vaccine elicits a strong rift valley fever virus neutralizing antibody response in sheep

Vector-Borne and Zoonotic Diseases

Volumn 14, Issue 10, 2014, Pages 746-756

  Faburay, Bonto ^a   Lebedev, Maxim ^b   McVey, D Scott ^c   Wilson, William ^c   Morozov, Igor ^a   Young, Alan ^b   Richt, Juergen A ^a  

^a KANSAS STATE UNIVERSITY   (United States)

^b SOUTH DAKOTA STATE UNIVERSITY   (United States)

^c AGRICULTURAL RESEARCH SERVICE   (United States)

Author keywords

Glycoproteins; Neutralizing antibodies; Rift Valley fever virus; Sheep; Subunit vaccine

Indexed keywords

ANTIGEN; GLYCOPROTEIN; NEUTRALIZING ANTIBODY; NUCLEOCAPSID PROTEIN; RECOMBINANT PROTEIN; STRUCTURAL PROTEIN; SUBUNIT VACCINE; VIRUS PROTEIN; VIRAL PROTEIN; VIRUS ANTIBODY; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION SYSTEM; IMMUNOGENICITY; NONHUMAN; RIFT VALLEY FEVER BUNYAVIRUS; SERODIAGNOSIS; SHEEP; ANIMAL; BACULOVIRIDAE; BIOSYNTHESIS; CHLOROCEBUS AETHIOPS; GENETICS; HUMAN; IMMUNOLOGY; INSECT VECTOR; METABOLISM; MOSQUITO; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; VACCINATION; VERO CELL LINE; VETERINARY; VIROLOGY; ZOONOSIS;

OVIS ARIES; RIFT VALLEY FEVER VIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; BACULOVIRIDAE; CERCOPITHECUS AETHIOPS; CULICIDAE; ENZYME-LINKED IMMUNOSORBENT ASSAY; GLYCOPROTEINS; HUMANS; INSECT VECTORS; RECOMBINANT PROTEINS; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SHEEP; VACCINATION; VACCINES, SUBUNIT; VERO CELLS; VIRAL PROTEINS; VIRAL VACCINES; ZOONOSES;

EID: 84912034025     PISSN: 15303667     EISSN: 15577759     Source Type: Journal    
DOI: 10.1089/vbz.2014.1650     Document Type: Article

References (60)

1. Besselaar TG, Blackburn NK. The synergistic neutralization of Rift Valley fever virus by monoclonal antibodies to the envelope glycoproteins. Arch Virol 1992; 125:239-250.
2. Besselaar TG, Blackburn NK. The effect of neutralizing monoclonal antibodies on early events in Rift Valley fever virus infectivity. Res Virol 1994; 145:13-19.
3. Besselaar TG, Blackburn NK, Meenehan GM. Antigenic analysis of Rift Valley fever virus isolates: Monoclonal antibodies distinguish between wild-type and neurotropic virus strains. Res Virol 1991; 142:469-474.
4. Billecocq A, Spiegel M, Vialat P, Kohl A, et al. NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. J Virol 2004;78:9798-9806.
5. Billecocq A, Gauliard N, Le Nay N, Elliott RM, et al. RNA polymerase I-mediated expression of viral RNA for the rescue of infectious virulent and avirulent Rift Valley fever viruses. Virology 2008; 378:377-384.
6. Bird B, Albarino C, Hartman A, Erickson B, et al. Rift valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals. J Virol 2008; 82:2681-2691.
7. Bird BH, Ksiazek TG, Nichol ST, Maclachlan NJ. Rift Valley fever virus. J Am Vet Med Assoc 2009; 234:883-893.
8. Bird BH, Maartens LH, Campbell S, Erasmus BJ, et al. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep. J Virol 2011; 85:12901-12909.
9. Botros B, Omar A, Elian K, Mohamed G, et al. Adverse effect of non-indigenous cattle of European breeds to live-attenuated Smithburn Rift Valley fever vaccine. J Med Virol 2006; 78:787-791.
10. Bouloy M, Flick R. Reverse genetics technology for Rift Valley fever virus: Current and future applications for the development of therapeutics and vaccines. Antiviral Res 2009;84:101-118.
11. Bouloy M, Janzen C, Vialat P, Khun H, et al. Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus nonstructural protein NSs. J Virol 2001; 75:1371-1377.
12. Caplen H, Peters CJ, Bishop DH. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 1985; 66( Pt 10):2271-2277.
13. Coetzer JA, Barnard BJ. Hydrops amnii in sheep associated with hydranencephaly and arthrogryposis with Wesselsbron disease and Rift Valley fever viruses as aetiological agents. Onderstepoort J Vet Res 1977; 44:119-126.
14. de Boer SM, Kortekaas J, Antonis AF, Kant J, et al. Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine 2010; 28:2330-2339.
15. Dodd KA, Bird BH, Metcalfe MG, Nichol ST, Albarino CG. Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge. J Virol 2012; 86:4204-12.
16. Dungu B, Louw I, Lubisi A, Hunter P, et al. Evaluation of the efficacy and safety of the Rift Valley fever clone 13 vaccine in sheep. Vaccine 2010; 28:4581-4587.
17. Elliott RM. The Bunyaviridae. New York: Plenum Press, 1996.
18. Faburay B, Wilson WC, McVey DS, Drolet BS, et al. Rift Valley fever virus structural and non-structural proteins: Recombinant protein expression and immunoreactivity against antisera from sheep. Vector Borne Zoonotic Dis 2013; 13:619-629.
19. Flick R, Bouloy M. Rift Valley fever virus. Curr Mol Med 2005; 5:827-834.
20. Gerrard SR, Nichol ST. Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins. Virology 2007;357:124-133.
21. Grobbelaar AA, Weyer J, Leman PA, Kemp A, et al. Molecular epidemiology of Rift Valley fever virus. Emerg Infect Dis 2011; 17:2270-2276.
22. Habjan M, Penski N, Spiegel M, Weber F. T7 RNA polymerase-dependent and -independent systems for cDNA-based rescue of Rift Valley fever virus. J Gen Virol 2008; 89:2157-2166.
23. Habjan M, Pichlmair A, Elliott RM, Överby AK, et al. NSs Protein of Rift Valley fever virus induces the specific degradation of the double-stranded RNA-dependent protein kinase. J Virol 2009; 83:4365-4375.
24. Heald R. Infectious disease surveillance update: Rift Valley fever in Mauritania. Lancet Infect Dis 2012; 12:915.
25. Heise MT, Whitmore A, Thompson J, Parsons M, et al. An alphavirus replicon-derived candidate vaccine against Rift Valley fever virus. Epidemiol Infect 2009; 137:1309-1318.
26. Hunter P, Erasmus B, Vorster J. Teratogenicity of a mutagenised Rift Valley fever virus (MVP 12) in sheep. Onderstepoort J Vet Res 2002; 69:95-98.
27. Ikegami T, Narayanan K, Won S, Kamitani W, et al. Rift Valley fever virus NSs protein promotes post-transcriptional down-regulation of protein kinase PKR and inhibits eIF2α phosphorylation. PLoS Pathog 2009; 5:e1000287.
28. Ikegami T, Won S, Peters C, Makino S. Rescue of infectious Rift Valley fever virus entirely from cDNA, analysis of virus lacking the NSs gene, and expression of a foreign gene. J Virol 2006; 80:2933-2940.
29. Kading RC, Crabtree MB, Bird BH, Nichol ST, et al. Deletion of the NSm virulence gene of Rift Valley fever virus inhibits virus replication in and dissemination from the midgut of Aedes aegypti mosquitoes. PLoS Negl Trop Dis 2014; 8:e2670.
30. Kortekaas J, de Boer SM, Kant J, Vloet RP, et al. Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine 2010a; 28:4394-4401.
31. Kortekaas J, Dekker A, de Boer SM, Weerdmeester K, et al. Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus. Vaccine 2010b; 28:2271-2276.
32. Kortekaas J, Oreshkova N, Cobos-Jimenez V, Vloet RP, et al. Creation of a nonspreading Rift Valley fever virus. J Virol 2011; 85:12622-12630.
33. Kortekaas J, Antonis AF, Kant J, Vloet RP, et al. Efficacy of three candidate Rift Valley fever vaccines in sheep. Vaccine 2012; 30:3423-3429.
34. Lagerqvist N, Naslund J, Lundkvist A, Bouloy M, et al. Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs. Virol J 2009;6:6.
35. Le May N, Dubaele S, De Santis LP, Billecocq A, et al. TFIIH transcription factor, a target for the Rift Valley hemorrhagic fever virus. Cell 2004; 116:541-550.
36. Le May N, Mansuroglu Z, Leger P, Josse T, et al. A SAP30 complex inhibits IFN-beta expression in Rift Valley fever virus infected cells. PLoS Pathog 2008;4:e13.
37. Liu L, Celma C, Roy P. Rift Valley fever virus structural proteins: Expression, characterization and assembly of recombinant proteins. Virol J 2008; 5:82.
38. Lubroth J, Rweyemamu MM, Viljoen G, Diallo A, et al. Veterinary vaccines and their use in developing countries. Rev Sci Tech 2007; 26:179-201.
39. Mandell RB, Koukuntla R, Mogler LJ, Carzoli AK, et al. A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge. Virology 2010a; 397:187-198.
40. Mandell RB, Koukuntla R, Mogler LJ, Carzoli AK, et al. Novel suspension cell-based vaccine production systems for Rift Valley fever virus-like particles. J Virol Methods 2010b; 169:259-268.
41. Morrill J, Mebus C, Peters C. Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle. Am J Vet Res 1997; 58:1104-1109.
42. Morrill JC, Laughlin RC, Lokugamage N, Pugh R, et al. Safety and immunogenicity of recombinant Rift Valley fever MP-12 vaccine candidates in sheep. Vaccine 2013; 31:559-565.
43. Muller R, Saluzzo JF, Lopez N, Dreier T, et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg 1995; 53:405-411.
44. Naslund J, Lagerqvist N, Habjan M, Lundkvist A, et al. Vaccination with virus-like particles protects mice from lethal infection of Rift Valley fever virus. Virology 2009; 385:409-415.
45. Oreshkova N, van Keulen L, Kant J, Moormann RJ, et al. A single vaccination with an improved nonspreading Rift Valley fever virus vaccine provides sterile immunity in lambs. PLoS One 2013; 8:e77461.
46. Papin JF, Verardi PH, Jones LA, Monge-Navarro F, et al. Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice. Proc Natl Acad Sci USA 2011; 108:14926-14931.
47. Paweska J, van Vuren P, Kemp A, Buss P, et al. Recombinant nucleocapsid-based ELISA for detection of IgG antibody to Rift Valley fever virus in African buffalo. Vet Microbiol 2008; 127:21-28.
48. Safety and immunogenicity of live-attenuated MP-12 Rift Valley fever vaccine (ZH548, MP12, TSI-GSD-223 Lot 7-2-88) in humans, and genetic characterization of virus isolates recovered from blood of vaccinated volunteers: A phase II study, 2012. https://clinicaltrials.gov/ct2/show/NCT00415051?term=safety+and+immunogenicity+of+live+attenuated+MP-12+Rift+Valley+ fever +vaccine&rank=1 Last accessed date October 9, 2014.
49. Pittman P, Liu C, Cannon T, Makuch R, Mangiafico J, et al. Immunogenicity of an inactivated Rift Valley fever vaccine in humans: A 12-year experience. Vaccine 2000; 18:181-189.
50. Schmaljohn CS, Parker MD, Ennis WH, Dalrymple JM, et al. Baculovirus expression of the M genome segment of Rift Valley fever virus and examination of antigenic and immunogenic properties of the expressed proteins. Virology 1989; 170:184-192.
51. Schmaljohn CS, Nichol ST. Bunyaviridae. In: Knippe DM, Howley PM, eds. Fields Virology, 5th ed, vol. 2. Philadelphia: Lippincott Williams & Wilkins, 2006:1741-1789.
52. Smith J, Tarawali S, Wright I, Bertrand S, et al. Livestock research for Africa's food security and poverty reduction. The 6th Africa Agriculture Science Week, Accra, Ghana, July 15-20, 2013. International Livestock Research Institute, Nairobi, Kenya, 2013.
53. Smithburn KC. Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol 1949; 30:1-16.
54. Spik K, Shurtleff A, McElroy AK, Guttieri MC, et al. Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus. Vaccine 2006; 24:4657-4666.
55. Swanepoel R, Coetzer J. Rift Valley fever. In: Coetzer JAW, Thomson GR, Tustin RC (ed), Infectious diseases of livestock with special reference to South Africa. Oxford University Press, Cape Town, South Africa, 1994; pp. 688-717.
56. Swanepoel R, Struthers JK, Erasmus MJ, Shepherd SP, et al. Comparison of techniques for demonstrating antibodies to Rift Valley fever virus. J Hyg (Lond) 1986; 97:317-329.
57. Vialat P, Muller R, Vu TH, Prehaud C, et al. Mapping of the mutations present in the genome of the Rift Valley fever virus attenuated MP12 strain and their putative role in attenuation. Virus Res 1997; 52:43-50.
58. Wallace DB, Ellis CE, Espach A, Smith SJ, et al. Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever. Vaccine 2006; 24:7181-7189.
59. Walter CT, Barr JN. Recent advances in the molecular and cellular biology of bunyaviruses: Review. J Gen Virol 2011; 92:2457-2484.
60. Won S, Ikegami T, Peters CJ, Makino S. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J Virol 2007; 81:13335-13345.